MedinCell S.A. is a biopharmaceutical company that develops long-acting injectable drugs using its proprietary BEPO technology. This technology allows for controlled drug delivery over several days, weeks, or months from a single injection. MedinCell focuses on various therapeutic areas, including schizophrenia, pain management, and contraception. Their target audience includes pharmaceutical companies and healthcare providers. The unique selling proposition is the innovative BEPO technology, which enhances medication compliance and effectiveness while reducing environmental impact. MedinCell collaborates with leading pharmaceutical companies to improve global health through new treatment options[1][2][3].